Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071331 · ClinicalTrials.gov registry record · Phase 3
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,600
- Enrollment target
NCT00071331 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 3,600 participants.
The verdict
NCT00071331, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,600 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
Interventions
- DRUG Tolvaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,600 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071331
The ClinicalTrials.gov registry entry for NCT00071331 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tolvaptan is the first listed.
NCT00071331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071331 about?
NCT00071331 is a clinical study titled "EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan". The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
What is the current status of trial NCT00071331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,600 participants. The study started on 2003-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00071331?
The interventions under investigation include: Tolvaptan (DRUG).
Who is sponsoring clinical trial NCT00071331?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.